- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04560062
Contextualizing the Evidence for Action on Diabetes - Cohort (CEAD)
Contextualizing Evidence for Action on Diabetes in Low-resource Settings: a Mixed-methods Case Study in Quito and Esmeraldas, Ecuador.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Objective: To evaluate the implementation of comprehensive diabetes care in two low-resource settings in Ecuador.
Specific objectives:
- To assess patient outcomes including biochemical diabetes control and health-related quality of life.
- To evaluate diabetes-related health care access.
- To assess complications related to diabetes.
Sample size: The sample size is proposed conservatively to ensure a precision to estimate outcomes of 50% with an absolute precision of ±5%, assuming a design effect of 1.2 and potential loss of 20%.
Sample design: A representative sample for each district will be obtained by stratified single-stage cluster sampling. The clusters are health facilities for which a sample of patients will randomly selected. The sample will be stratified by facility type (Ministry of Public Health (MSP) facilities, or Social Security facilities for affiliated workers) in Quito and by Rural/Urban setting in Esmeraldas. Patient sampling will use the electronic consultation registry of each selected facility where possible. Data unavailable in the electronic registers will be extracted from any available paper files.
Data collection procedure: Research assistants will obtain the data mainly from health services records, which will be supplemented by patient interviews including socio-demographic and clinical data, perceived social support (the Multidimensional Scale of Perceived Social Support, MSPSS) and health-related quality of life (the Diabetes Health Profile-18, DHP-18) profile. They will collect data regarding whether the patient received regular review by a clinician, and underwent screening for diabetes complications as recommended in the 2017 Clinical Practice Guideline for Type 2 Diabetes in Ecuador. He/she will record the date and details of any complications and experiences over the course of the evaluation and other clinical data such as comorbidities, treatments or patient management by a multidisciplinary health care team.
The first data collection will be retrospective and will include diabetes-related health care and clinical outcomes during 2019 and 2020. Clinical files will be reviewed every 12 months for the duration of follow-up (2 years). Supplementary interview data will be assessed on a baseline and in the last 6 months of follow-up.
Analysis: The researchers will calculate the proportion of patients that received care as per the clinical practice guideline (CPG) recommendations and/or the proportion receiving an intermediate level of care (as required). Proportions will be described with 95% confidence intervals. Variation in healthcare received and diabetes-related health will be described using sociodemographic and clinical characteristics of the patients to highlight potential inequities. A multivariate logistic regression model may be used to explore the relationship between the primary outcomes and socioeconomic explanatory variable and/or type of health facility. If necessary, the researchers will adjust for potential confounders such as patients' factors (e.g. sex, age, comorbidity, perceived social support) and/or environmental factors (e.g. proximity to the health centre, availability of different medical specialties or methods as laboratory test). Statistical analysis will be performed using Stata/SE (StataCorp, College Station, TX, USA) Version 15.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Lucy Anne Parker
- Phone Number: +34 965919516
- Email: lparker@umh.es
Study Contact Backup
- Name: Mari Carmen Bernal Soriano
- Email: maria.bernals@umh.es
Study Locations
-
-
-
Esmeraldas, Ecuador, 080102
- Recruiting
- Mari Carmen Bernal Soriano
-
Contact:
- Mari Carmen Bernal Soriano
- Email: maria.bernals@umh.es
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Individuals diagnosed with type-2 diabetes.
- Age over 18 years.
- Patients are accessing diabetes care in health facilities in the study districts.
- Providing informed consent
Exclusion Criteria:
- Unability to provide informed consent (e.g. significant mental impairment).
- Pregnant women if they are diagnosed with gestational diabetes.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Population in Quito
576 randomly chosen patients with diabetes in District 17D06, Quito (Ecuador)
|
The findings of a retrospective cohort analysis conducted in the initial phase of the study will be used in focus groups to identify observed weaknesses in local health systems and will promote possible solutions to strengthen diabetes-related health care.
Every focus group will include community members, healthcare workers, decision-makers and diabetic patients and family members.
|
Population in Esmeraldas
576 randomly chosen patients with diabetes in Eloy Alfaro District, Esmeraldas (Ecuador)
|
The findings of a retrospective cohort analysis conducted in the initial phase of the study will be used in focus groups to identify observed weaknesses in local health systems and will promote possible solutions to strengthen diabetes-related health care.
Every focus group will include community members, healthcare workers, decision-makers and diabetic patients and family members.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of patients with biochemically controlled disease
Time Frame: Year 1
|
Proportions of patients with controlled disease along with 95% confidence interval. Controlled disease is defined according to the last laboratory result as glycated haemoglobin <7% or <8% if ≥15 years of evolution or complications and serious comorbidities; or fasting blood glucose: 70 - 130 mg/dl or postprandial blood glucose <180 mg/dl. |
Year 1
|
Proportion of patients with biochemically controlled disease
Time Frame: Year 2
|
Proportions of patients with controlled disease along with 95% confidence interval. Controlled disease is defined according to the last laboratory result as glycated haemoglobin <7% or <8% if ≥15 years of evolution or complications and serious comorbidities; or fasting blood glucose: 70 - 130 mg/dl or postprandial blood glucose <180 mg/dl. |
Year 2
|
Proportion of patients with biochemically controlled disease
Time Frame: Year 3
|
Proportions of patients with controlled disease along with 95% confidence interval. Controlled disease is defined according to the last laboratory result as glycated haemoglobin <7% or <8% if ≥15 years of evolution or complications and serious comorbidities; or fasting blood glucose: 70 - 130 mg/dl or postprandial blood glucose <180 mg/dl. |
Year 3
|
Proportion of patients with biochemically controlled disease
Time Frame: Year 4
|
Proportions of patients with controlled disease along with 95% confidence interval. Controlled disease is defined according to the last laboratory result as glycated haemoglobin <7% or <8% if ≥15 years of evolution or complications and serious comorbidities; or fasting blood glucose: 70 - 130 mg/dl or postprandial blood glucose <180 mg/dl. |
Year 4
|
Proportion of patients with optimal health-related quality of life
Time Frame: Year 3
|
Health-related quality of life will be obtained with Diabetes Health Profile-18 (DHP-18) questionnaire. DHP-18 scores range from 0 to 100, with 0 representing no dysfunction and 100 maximum dysfunction. Proportion of patients with total final score under the median, meaning lower dysfunction, along with 95% confidence interval. |
Year 3
|
Proportion of patients with optimal health-related quality of life
Time Frame: Year 4
|
Health-related quality of life will be obtained with Diabetes Health Profile-18 (DHP-18) questionnaire. DHP-18 scores range from 0 to 100, with 0 representing no dysfunction and 100 maximum dysfunction. Proportion of patients with total final score under the median, meaning lower dysfunction, along with 95% confidence interval. |
Year 4
|
Proportion of patients with access to health care of diabetes
Time Frame: Year 1
|
It includes processes of care indicators that represent the proportion of the patients who undergo the care processes recommended by the CPG to manage the disease.
The investigators will obtain the care frequency for each patient during the year of study as a quantitative value and will also categorize those care indicators that are recommended with greater periodicity in the CPG.
|
Year 1
|
Proportion of patients with access to health care of diabetes
Time Frame: Year 2
|
It includes processes of care indicators that represent the proportion of the patients who undergo the care processes recommended by the CPG to manage the disease.
The investigators will obtain the care frequency for each patient during the year of study as a quantitative value and will also categorize those care indicators that are recommended with greater periodicity in the CPG.
|
Year 2
|
Proportion of patients with access to health care of diabetes
Time Frame: Year 3
|
It includes processes of care indicators that represent the proportion of the patients who undergo the care processes recommended by the CPG to manage the disease.
The investigators will obtain the care frequency for each patient during the year of study as a quantitative value and will also categorize those care indicators that are recommended with greater periodicity in the CPG.
|
Year 3
|
Proportion of patients with access to health care of diabetes
Time Frame: Year 4
|
It includes processes of care indicators that represent the proportion of the patients who undergo the care processes recommended by the CPG to manage the disease.
The investigators will obtain the care frequency for each patient during the year of study as a quantitative value and will also categorize those care indicators that are recommended with greater periodicity in the CPG.
|
Year 4
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Perceived social support
Time Frame: Year 3
|
Results of the standardized questionnaire "the Multidimensional Scale of Perceived Social Support (MSPSS)". The response format is a four-point Likert type scale (1= rarely, 2= sometimes, 3=frequently, 4= always or almost always). A higher score implies a greater perception of social support. Tertiles of total final score will be used to measure low, medium and high social support. The investigators will report the patient ratio and 95% confidence interval for each category of social support |
Year 3
|
Perceived social support
Time Frame: Year 4
|
Results of the standardized questionnaire "the Multidimensional Scale of Perceived Social Support (MSPSS)". The response format is a four-point Likert type scale (1= rarely, 2= sometimes, 3=frequently, 4= always or almost always). A higher score implies a greater perception of social support. Tertiles of total final score will be used to measure low, medium and high social support. The investigators will report the patient ratio and 95% confidence interval for each category of social support. |
Year 4
|
Proportion of patients who diabetes-related education received
Time Frame: Year 3
|
Self-reported information [dichotomous (yes/no) responses].
Proportion of patients who indicate that they have received information on diabetes and healthy habits, along with 95% confidence interval.
|
Year 3
|
Proportion of patients who diabetes-related education received
Time Frame: Year 4
|
Self-reported information [dichotomous (yes/no) responses].
Proportion of patients who indicate that they have received information on diabetes and healthy habits, along with 95% confidence interval.
|
Year 4
|
Proportion of patients with blood pressure controlled (<140/90 mmHg)
Time Frame: Year 1
|
Proportions along with 95% confidence interval.
|
Year 1
|
Proportion of patients with blood pressure controlled (<140/90 mmHg)
Time Frame: Year 2
|
Proportions along with 95% confidence interval.
|
Year 2
|
Proportion of patients with blood pressure controlled (<140/90 mmHg)
Time Frame: Year 3
|
Proportions along with 95% confidence interval.
|
Year 3
|
Proportion of patients with blood pressure controlled (<140/90 mmHg)
Time Frame: Year 4
|
Proportions along with 95% confidence interval.
|
Year 4
|
Proportion of patients with BMI between 18.5 and 25 kg/m2 or 5% weight loss if BMI>25 kg/m2
Time Frame: Year 1
|
Proportions along with 95% confidence interval.
|
Year 1
|
Proportion of patients with BMI between 18.5 and 25 kg/m2 or 5% weight loss if BMI>25 kg/m2
Time Frame: Year 2
|
Proportions along with 95% confidence interval.
|
Year 2
|
Proportion of patients with BMI between 18.5 and 25 kg/m2 or 5% weight loss if BMI>25 kg/m2
Time Frame: Year 3
|
Proportions along with 95% confidence interval.
|
Year 3
|
Proportion of patients with BMI between 18.5 and 25 kg/m2 or 5% weight loss if BMI>25 kg/m2
Time Frame: Year 4
|
Proportions along with 95% confidence interval.
|
Year 4
|
Proportion of patients with LDL cholesterol level < 100 mg/dl
Time Frame: Year 1
|
Proportions along with 95% confidence interval.
|
Year 1
|
Proportion of patients with LDL cholesterol level < 100 mg/dl
Time Frame: Year 2
|
Proportions along with 95% confidence interval.
|
Year 2
|
Proportion of patients with LDL cholesterol level < 100 mg/dl
Time Frame: Year 3
|
Proportions along with 95% confidence interval.
|
Year 3
|
Proportion of patients with LDL cholesterol level < 100 mg/dl
Time Frame: Year 4
|
Proportions along with 95% confidence interval.
|
Year 4
|
Proportion of patients with microalbuminuria level <30 mg/day
Time Frame: Year 1
|
Proportions along with 95% confidence interval.
|
Year 1
|
Proportion of patients with microalbuminuria level <30 mg/day
Time Frame: Year 2
|
Proportions along with 95% confidence interval.
|
Year 2
|
Proportion of patients with microalbuminuria level <30 mg/day
Time Frame: Year 3
|
Proportions along with 95% confidence interval.
|
Year 3
|
Proportion of patients with microalbuminuria level <30 mg/day
Time Frame: Year 4
|
Proportions along with 95% confidence interval.
|
Year 4
|
Number of unscheduled diabetes-related consultations
Time Frame: Year 1
|
Number of unscheduled due to decompensation of the disease and/or complications.
Results will be reported as absolute values.
|
Year 1
|
Number of unscheduled diabetes-related consultations
Time Frame: Year 2
|
Number of unscheduled due to decompensation of the disease and/or complications.
Results will be reported as absolute values.
|
Year 2
|
Number of unscheduled diabetes-related consultations
Time Frame: Year 3
|
Number of unscheduled due to decompensation of the disease and/or complications.
Results will be reported as absolute values.
|
Year 3
|
Number of unscheduled diabetes-related consultations
Time Frame: Year 4
|
Number of unscheduled due to decompensation of the disease and/or complications.
Results will be reported as absolute values.
|
Year 4
|
Number of hospitalisations due to diabetes complications
Time Frame: Year 1
|
Number of hospitalisations owing to decompensation of the disease and/or complications.
Results will be reported as absolute values.
|
Year 1
|
Number of hospitalisations due to diabetes complications
Time Frame: Year 2
|
Number of hospitalisations owing to decompensation of the disease and/or complications.
Results will be reported as absolute values.
|
Year 2
|
Number of hospitalisations due to diabetes complications
Time Frame: Year 3
|
Number of hospitalisations owing to decompensation of the disease and/or complications.
Results will be reported as absolute values.
|
Year 3
|
Number of hospitalisations due to diabetes complications
Time Frame: Year 4
|
Number of hospitalisations owing to decompensation of the disease and/or complications.
Results will be reported as absolute values.
|
Year 4
|
Proportion of patients with at least one disease complication
Time Frame: Year 1
|
Disease complications considered will include retinopathy and/or blindness, lower limb amputations, cardiovascular events (such as stroke, myocardial infarction, ischemic heart disease, obstructive artery disease, congestive heart failure) and/or renal dysfunction according to the last glomerular filtration rate result using the MDRD-4 (Modification of Diet in Renal Disease) formula or serum creatinine value. Proportion along with 95% confidence interval. |
Year 1
|
Proportion of patients with at least one disease complication
Time Frame: Year 2
|
Disease complications considered will include retinopathy and/or blindness, lower limb amputations, cardiovascular events (such as stroke, myocardial infarction, ischemic heart disease, obstructive artery disease, congestive heart failure) and/or renal dysfunction according to the last glomerular filtration rate result using the MDRD-4 (Modification of Diet in Renal Disease) formula or serum creatinine value. Proportion along with 95% confidence interval. |
Year 2
|
Proportion of patients with at least one disease complication
Time Frame: Year 3
|
Disease complications considered will include retinopathy and/or blindness, lower limb amputations, cardiovascular events (such as stroke, myocardial infarction, ischemic heart disease, obstructive artery disease, congestive heart failure) and/or renal dysfunction according to the last glomerular filtration rate result using the MDRD-4 (Modification of Diet in Renal Disease) formula or serum creatinine value. Proportion along with 95% confidence interval. |
Year 3
|
Proportion of patients with at least one disease complication
Time Frame: Year 4
|
Disease complications considered will include retinopathy and/or blindness, lower limb amputations, cardiovascular events (such as stroke, myocardial infarction, ischemic heart disease, obstructive artery disease, congestive heart failure) and/or renal dysfunction according to the last glomerular filtration rate result using the MDRD-4 (Modification of Diet in Renal Disease) formula or serum creatinine value. Proportion along with 95% confidence interval. |
Year 4
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Lucy A Parker, PhD, University Miguel Hernandez
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ERC-2018-STG-804761.2
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
AstraZenecaRecruiting
-
Daewoong Pharmaceutical Co. LTD.Not yet recruitingT2DM (Type 2 Diabetes Mellitus)
-
Zhongda HospitalRecruitingType 2 Diabetes Mellitus (T2DM)China
-
Newsoara Biopharma Co., Ltd.RecruitingT2DM (Type 2 Diabetes Mellitus)China
-
Shanghai Golden Leaf MedTec Co. LtdActive, not recruitingType 2 Diabetes Mellitus (T2DM)China
Clinical Trials on Spontaneous changes in diabetes-related health care
-
Azienda Socio Sanitaria Territoriale degli Spedali...CompletedGynecologic Cancer | Surgery | Anesthesia | Hysterectomy | Gynecologic DiseaseItaly
-
Lahey ClinicPfizerCompletedDiabetes Mellitus, Type 2United States
-
Hospices Civils de LyonCompletedDiabete Type 2 | Diabete Type 1France
-
QualiCCareNovo Nordisk A/S; Sanofi; Swiss Society of Endocrinology and Diabetology; Roche... and other collaboratorsCompletedDiabetes Mellitus, Type 2 | Primary CareSwitzerland
-
NYU Langone HealthNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedCystinuria | Primary Hyperoxaluria | Dent Disease | Adenine Phosphoribosyl Transferase DeficiencyUnited States, Iceland
-
Queen's UniversityUniversity of GondarCompletedDiabetes Mellitus, Type 2 | Type 2 DiabetesCanada
-
Mohd Khairul Zul Hasymi FirdausPrince of Songkla UniversityCompletedDiabetes Mellitus, Type 2Malaysia
-
Indonesia UniversityProvincial Health Services AuthorityRecruitingDiabetes Mellitus, Type 2 | Diabetes Mellitus | Endocrine System Diseases | Type2 Diabetes | Nutritional and Metabolic Diseases | Glucose Metabolism Disorders (Including Diabetes Mellitus)Indonesia
-
University of TwenteZiekenhuisgroep TwenteRecruitingDiabetes Mellitus, Type 2Netherlands
-
Forschungsinstitut der Diabetes Akademie MergentheimGerman Federal Ministry of Education and Research; Helmholtz Zentrum München; German Diabetes Center and other collaboratorsCompletedDepression | Diabetes Mellitus | Diabetes Complications | Depressive Symptoms | Emotional Distress | Affective DisordersGermany